MarketScreener Editorial Features Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.96 USD | +1.18% |
|
+6.13% | +63.74% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
MarketScreener Editorial Features
Search
 | Global markets live: Amazon, AWS, Lufthansa, Saudi Aramco, Standard Chartered… | March 02, 2026 at 09:22 am EST |
 | The new silk road of optimism | October 27, 2025 at 10:22 am EDT |
 | Today on Wall Street: The start of a new phase | June 30, 2021 at 08:47 am EDT |
 | Analyst recommendations: Apple, FedEx, Intellia Therapeutics, Reckitt Benckiser, XPO Logistics... | June 30, 2021 at 06:12 am EDT |
No results for this search
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- MarketScreener Editorial Features
Select your edition
All financial news and data tailored to specific country editions
